Agios Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AGIO) $22.05 -1.09 (-4.71%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$22.01▼$23.1450-Day Range$19.97▼$24.5352-Week Range$19.80▼$31.87Volume392,101 shsAverage Volume391,638 shsMarket Capitalization$1.23 billionP/E RatioN/ADividend YieldN/APrice Target$35.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Agios Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside59.6% Upside$35.20 Price TargetShort InterestBearish10.99% of Float Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment0.61Based on 5 Articles This WeekInsider TradingSelling Shares$54,017 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.25) to ($4.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector657th out of 942 stocksPharmaceutical Preparations Industry315th out of 448 stocks 3.3 Analyst's Opinion Consensus RatingAgios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.20, Agios Pharmaceuticals has a forecasted upside of 59.6% from its current price of $22.05.Amount of Analyst CoverageAgios Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.99% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in Agios Pharmaceuticals has recently increased by 6.36%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgios Pharmaceuticals has received a 73.83% net impact score from Upright. Agios Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agios Pharmaceuticals is -0.60. Previous Next 2.6 News and Social Media Coverage News SentimentAgios Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Agios Pharmaceuticals this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $54,017.00 in company stock.Percentage Held by InsidersOnly 4.24% of the stock of Agios Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.25) to ($4.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Agios Pharmaceuticals Stock (NASDAQ:AGIO)Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More AGIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGIO Stock News HeadlinesDecember 9, 2023 | americanbankingnews.comQ3 2024 Earnings Estimate for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Issued By Zacks ResearchDecember 6, 2023 | finance.yahoo.comAgios Pharmaceuticals (NASDAQ:AGIO) shareholders have endured a 59% loss from investing in the stock five years agoDecember 9, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 22, 2023 | thestreet.comCramer: Agios Pharmaceuticals' Leukemia Drug Pushing Stock 'Much Higher'November 20, 2023 | finance.yahoo.comAgios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic SyndromesNovember 6, 2023 | markets.businessinsider.comAgios Pharma Stock Receives ‘Buy’ Rating: Promising Financial Results, Pipeline Updates, and Upcoming Catalysts Justify OptimismNovember 5, 2023 | benzinga.comAgios Pharmaceuticals Stock (NASDAQ:AGIO), Analyst Ratings, Price Targets, PredictionsNovember 5, 2023 | finance.yahoo.comCalculating The Fair Value Of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)December 9, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 3, 2023 | markets.businessinsider.comAgios Pharma’s Promising Outlook: Expanding Pyruvate Kinase Activator Portfolio, Clinical Progress and Solid Financial Stability Prompt Buy RatingNovember 3, 2023 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | seekingalpha.comAgios Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 2, 2023 | msn.comAgios Pharmaceuticals GAAP EPS of -$1.64 beats by $0.06, revenue of $7.4M misses by $0.13MNovember 2, 2023 | finance.yahoo.comAgios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and ExpositionNovember 2, 2023 | finance.yahoo.comAgios Pharmaceuticals Inc (AGIO) Reports Q3 2023 Earnings, Reveals 10% Increase in U.S. Net RevenueNovember 1, 2023 | msn.comAgios Pharmaceuticals Q3 2023 Earnings PreviewOctober 19, 2023 | finance.yahoo.comAgios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023September 14, 2023 | markets.businessinsider.comNektar Therapeutics (NKTR) Gets a Sell from Bank of America SecuritiesSeptember 9, 2023 | finanznachrichten.deRegeneron Pharmaceuticals, Inc.: Regeneron Announces Updates to Board of DirectorsSeptember 7, 2023 | finance.yahoo.comWhy Is Haemonetics (HAE) Down 1.9% Since Last Earnings Report?September 3, 2023 | markets.businessinsider.comJ.P. Morgan Reaffirms Their Hold Rating on Sana Biotechnology (SANA)August 30, 2023 | uk.finance.yahoo.comAgios Pharmaceuticals Inc (8AP.BE)August 29, 2023 | finance.yahoo.comAgios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023August 22, 2023 | benzinga.comAgios Pharmaceuticals Insider Trades Send a SignalAugust 10, 2023 | benzinga.comPrincipal Accounting Officer At This Health Care Company Sells $74K of StockAugust 10, 2023 | finance.yahoo.comThe Petri Dish: Agios licenses Alnylam drug, Ikena acquires startup with Gilead stakeAugust 8, 2023 | msn.comJP Morgan Maintains Agios Pharmaceuticals (AGIO) Neutral RecommendationSee More Headlines Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/09/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGIO CUSIPN/A CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees389Year FoundedN/APrice Target and Rating Average Stock Price Target$35.20 High Stock Price Target$41.00 Low Stock Price Target$28.00 Potential Upside/Downside+59.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-231,800,000.00 Net Margins-913.95% Pretax Margin-913.95% Return on Equity-22.03% Return on Assets-19.60% Debt Debt-to-Equity RatioN/A Current Ratio12.06 Quick Ratio11.76 Sales & Book Value Annual Sales$14.24 million Price / Sales86.54 Cash FlowN/A Price / Cash FlowN/A Book Value$20.03 per share Price / Book1.10Miscellaneous Outstanding Shares55,890,000Free Float53,521,000Market Cap$1.23 billion OptionableOptionable Beta0.93 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Brian M. Goff M.B.A. (Age 54)CEO & Director Comp: $1.23MMs. Cecilia Jones (Age 48)Chief Financial Officer Comp: $403.36kMr. James William Burns (Age 45)Corporate Secretary & Chief Legal Officer Comp: $660.33kDr. Sarah Gheuens M.D. (Age 43)Ph.D., Chief Medical Officer and Head of Research & Development Comp: $769.2kDr. Lewis Clayton Cantley Ph.D. (Age 74)Co-Founder & Member of Scientific Advisory Board Comp: $50kDr. Tak Wah Mak D.Sc. (Age 77)FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Craig B. Thompson M.D. (Age 70)Co-Founder & Chairman of Scientific Advisory Board Dr. Shin-San Su Ph.D. (Age 67)Co-Founder & Member of Scientific Advisory Board Mr. T. J. Washburn Jr. (Age 42)Principal Accounting Officer Dr. Clive Patience Ph.D. (Age 59)Chief Technical Operations Officer More ExecutivesKey CompetitorsAurinia PharmaceuticalsNASDAQ:AUPHSage TherapeuticsNASDAQ:SAGEMorphicNASDAQ:MORFArvinasNASDAQ:ARVNOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsHudson Bay Capital Management LPBought 10,000 shares on 12/7/2023Ownership: 0.483%Citigroup Inc.Bought 28,800 shares on 12/6/2023Ownership: 0.000%Wellington Management Group LLPSold 666,565 shares on 12/1/2023Ownership: 9.302%American Century Companies Inc.Bought 10,261 shares on 11/30/2023Ownership: 0.083%Deutsche Bank AGBought 3,626 shares on 11/24/2023Ownership: 1.041%View All Insider TransactionsView All Institutional Transactions AGIO Stock Analysis - Frequently Asked Questions Should I buy or sell Agios Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AGIO shares. View AGIO analyst ratings or view top-rated stocks. What is Agios Pharmaceuticals' stock price target for 2024? 4 Wall Street research analysts have issued 1 year price objectives for Agios Pharmaceuticals' stock. Their AGIO share price targets range from $28.00 to $41.00. On average, they expect the company's share price to reach $35.20 in the next twelve months. This suggests a possible upside of 59.6% from the stock's current price. View analysts price targets for AGIO or view top-rated stocks among Wall Street analysts. How have AGIO shares performed in 2023? Agios Pharmaceuticals' stock was trading at $28.08 at the beginning of 2023. Since then, AGIO shares have decreased by 21.5% and is now trading at $22.05. View the best growth stocks for 2023 here. Are investors shorting Agios Pharmaceuticals? Agios Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 6,020,000 shares, an increase of 6.4% from the October 31st total of 5,660,000 shares. Based on an average daily volume of 531,600 shares, the days-to-cover ratio is currently 11.3 days. Currently, 11.0% of the shares of the company are short sold. View Agios Pharmaceuticals' Short Interest. When is Agios Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our AGIO earnings forecast. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.69) by $0.05. The biopharmaceutical company earned $7.40 million during the quarter, compared to the consensus estimate of $7.73 million. Agios Pharmaceuticals had a negative net margin of 913.95% and a negative trailing twelve-month return on equity of 22.03%. What ETFs hold Agios Pharmaceuticals' stock? ETFs with the largest weight of Agios Pharmaceuticals (NASDAQ:AGIO) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA) and ALPS Medical Breakthroughs ETF (SBIO).Simplify Propel Opportunities ETF (SURI). What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO? 11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX). Who are Agios Pharmaceuticals' major shareholders? Agios Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (9.30%), Armistice Capital LLC (5.95%), Rock Springs Capital Management LP (4.85%), JPMorgan Chase & Co. (4.42%), Northern Trust Corp (1.10%) and Deutsche Bank AG (1.04%). Insiders that own company stock include Brian Goff, Carman Alenson, Cecilia Jones, Christopher Bowden, Darrin Miles, David P Schenkein, Jacqualyn A Fouse, James William Burns, Kaye I Foster-Cheek and Theodore James Jr Washburn. View institutional ownership trends. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AGIO) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.